PMID: 8950524Sep 1, 1996Paper

Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to trovafloxacin

Diagnostic Microbiology and Infectious Disease
H F BonillaC A Kauffman

Abstract

The susceptibilities of clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) and enterococci obtained over a 13-year period were tested for trovafloxacin, a new fluoroquinolone, and ciprofloxacin. For MRSA, MIC50 values for trovafloxacin increased from 0.03 microgram/ml to 1 microgram/ml from 1984-1985 to 1995-1996, but were lower than those noted for ciprofloxacin, which increased from 0.25 microgram/ml to > 8 micrograms/ml during the same period. Trovafloxacin also showed lower MIC50 values (0.12-0.25 microgram/ml) than ciprofloxacin (MIC50 of 0.5-1 microgram/ml) for E. faecalis isolates from 1985 through 1991, but against E. faecium and E. faecalis isolated in 1995-1996, the MIC50 values for both trovafloxacin and ciprofloxacin were 2 micrograms/ml and the MIC90 values were > or 8 micrograms/ml. Thus, cross-resistance between fluoroquinolones was shown for both enterococci and MRSA. Whether the greater intrinsic activity of trovafloxacin might allow its use in treating MRSA and enterococcal infections remains to be seen.

References

Nov 1, 1992·Antimicrobial Agents and Chemotherapy·D R SchabergC A Kauffman
Mar 1, 1992·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·L J StrausbaughT T Ward
Jun 11, 1992·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·R C Moellering
Sep 16, 1991·The American Journal of Medicine·D R SchabergR P Gaynes
Jun 1, 1991·The Journal of Infectious Diseases·H M BlumbergI K Wachsmuth
Sep 1, 1990·Antimicrobial Agents and Chemotherapy·T E DaumC A Kauffman
Jan 1, 1989·Antimicrobial Agents and Chemotherapy·D F Sahm, G T Koburov
May 1, 1987·Annals of Internal Medicine·M J ZervosD R Schaberg
Jan 1, 1988·The Journal of Antimicrobial Chemotherapy·M J ZervosC A Kauffman
Jan 1, 1995·Diagnostic Microbiology and Infectious Disease·G D HarringtonC A Kauffman
Jan 1, 1995·Diagnostic Microbiology and Infectious Disease·B L Prosser, G Beskid
Nov 1, 1994·Antimicrobial Agents and Chemotherapy·H C Neu, N X Chin
Feb 1, 1993·Antimicrobial Agents and Chemotherapy·B B Gooding, R N Jones
Feb 1, 1994·Antimicrobial Agents and Chemotherapy·L J Piddock
Aug 1, 1993·Antimicrobial Agents and Chemotherapy·M Arthur, P Courvalin
Aug 1, 1993·Diagnostic Microbiology and Infectious Disease·M B PerriM J Zervos
Feb 1, 1993·Antimicrobial Agents and Chemotherapy·G M EliopoulosR C Moellering
Sep 1, 1995·Antimicrobial Agents and Chemotherapy·M A CohenC L Courtney

❮ Previous
Next ❯

Citations

Feb 19, 2000·Scandinavian Journal of Infectious Diseases·M RylanderG Kronvall
Feb 11, 1999·The Annals of Pharmacotherapy·A A Alghasham, M C Nahata
Apr 2, 1999·Antimicrobial Agents and Chemotherapy·N A el AminB Wretlind
Aug 4, 1998·Antimicrobial Agents and Chemotherapy·J E FitzgibbonD T Dubin
Apr 4, 1998·Antimicrobial Agents and Chemotherapy·G W KaatzM J Rybak

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy & Infectious Diseases

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Allergy & Infectious Diseases (ASM)

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.